Opendata, web and dolomites

BoVLP-BVD SIGNED

Tagged (DIVA) polyantigenic vaccine against Bovine Viral Diarrhea virus (BVDv) based on virus-Like-Particles

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BoVLP-BVD project word cloud

Explore the words cloud of the BoVLP-BVD project. It provides you a very rough idea of what is the project "BoVLP-BVD" about.

herd    recombinant    prototype    manufacturing    774994    environmental    exposed    becomes    approximately    species    licensed    internal    50    25    instrument    particle    trl8    million    5x    final    diva    reduce    complete    suboptimal       infectious    bovine    viral    diseases    point    endemic    biotech    candidate    commercialisation    persistent    livestock    herds    sme    vivo    vaccine    pressure    oacute    safety    90    productivity    multiplier    animal    fight    euros    virus    bodies    worldwide    agro    disease    had    vaccination    reproduction    patented    vaccines    diarrhea    cyl    programs    demonstrating    economic    agreements    ordm    systematic    rate    projections    milestones    countries    feasibility    social    pharmaceutical    bvdv    industry    attributes    regulatory    agent    hundreds    data    industrial    stage    veterinarian    company    royalties    aquil    commercial    efficacy    cattle    return    investment    bvd    hut    infection    business    positive    lifetime    trl6    antibiotics    animals    context    prevent    of    demonstrated    eradication    food    public   

Project "BoVLP-BVD" data sheet

The following table provides information about the project.

Coordinator
AQUILON CYL SOCIEDAD LIMITADA 

Organization address
address: LUGAR FACULTAD DE VETERINARIA S/N CAMPUS VEGAZANA
city: LEON
postcode: 24000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 2˙221˙042 €
 EC max contribution 1˙554˙729 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AQUILON CYL SOCIEDAD LIMITADA ES (LEON) coordinator 1˙554˙729.00

Map

 Project objective

In a general context of environmental, social and legal pressure to reduce the use of antibiotics to fight diseases in livestock animals, cost-effective vaccination becomes the focus of most of the industry, regulatory and agro-food public bodies. Development of new vaccines to prevent the disease and therefore avoid the use of antibiotics or to improve suboptimal available vaccines is now an European and industry priority. Bovine viral diarrhea virus (BVDV) is an important infectious agent of cattle worldwide that affects herd productivity and reproduction. BVD has been and is an endemic disease in all countries where no systematic eradication and control programs have been established. Under these conditions, approximately 50% of the herds have or have had animals with persistent infection, and approximately 90% of the cattle have been exposed to the virus at some point during their lifetime. Infection with BVDV has a major economic impact, estimated in hundreds of euros per animal for a European hut of around 80 million animals. Aquilón CyL, a leading biotech company, has developed new recombinant vaccine against BVDV using a Virus-Like- Particle patented technology. Aquilón has demonstrated the technical, commercial and regulatory feasibility by the SME instrument phase 1 project (nº 774994). After developing the vaccine to TRL6 stage (pre-industrial prototype with positive activity data), Aquilón will develop one vaccine to TRL8 stage, demonstrating the commercial-scale manufacturing and in-vivo safety, efficacy and DIVA attributes in the target species. This vaccine candidate will be licensed to one or more veterinarian pharmaceutical company that will complete the final field studies required for commercialisation. Our business projections, based on agreements with Development milestones and commercial royalties, show potential for a 5X investment multiplier with a 25% internal rate of return.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BOVLP-BVD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BOVLP-BVD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More